Bone Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.10.24	BioSenic provides third quarter 2024 Business Update (GlobeNewswire)
07.10.24	BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD. (GlobeNewswire)
30.09.24	BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the compositio (GlobeNewswire)
30.09.24	BioSenic reports half year 2024 results (GlobeNewswire)
17.09.24	Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO (GlobeNewswire)
19.08.24	BioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD. (GlobeNewswire)
14.08.24	Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis (GlobeNewswire)
13.08.24	Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform (GlobeNewswire)
13.08.24	BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD. (GlobeNewswire)
19.07.24	BioSenic S.A. : Transparency notification received from Mr François Rieger (GlobeNewswire)
18.07.24	BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD (GlobeNewswire)
12.07.24	BioSenic S.A. : Transparency notification received from Véronique Pomi (GlobeNewswire)
05.07.24	Medsenic, subsidiary of BioSenic SA, extends key patent to the United States (GlobeNewswire)
02.07.24	Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd. (GlobeNewswire)
28.06.24	BioSenic S.A. : Information on the total number of voting rights and shares (GlobeNewswire)
21.06.24	BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds (GlobeNewswire)
14.06.24	The Enterprise Court of Nivelles approves the BioSenic restructuring plan (GlobeNewswire)
12.06.24	BioSenic to host Annual General Meeting on July 12, 2024 (GlobeNewswire)
06.06.24	BioSenic announces 2023 full year results (GlobeNewswire)
31.05.24	BioSenic S.A. : Information on the total number of voting rights and shares (GlobeNewswire)
27.05.24	BioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles (GlobeNewswire)
24.05.24	BioSenic provides First Quarter 2024 Business Update (GlobeNewswire)
30.04.24	BioSenic S.A. : Information on the total number of voting rights and shares (GlobeNewswire)
26.04.24	BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles (GlobeNewswire)
24.04.24	BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023 (GlobeNewswire)
18.04.24	BioSenic S.A. : Transparency notifications received from François Rieger (GlobeNewswire)
12.04.24	BioSenic provides further information on its restructuring plan (GlobeNewswire)
11.04.24	BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles (GlobeNewswire)
29.03.24	BioSenic S.A. : Information on the total number of voting rights and shares (GlobeNewswire)
20.03.24	BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress (GlobeNewswire)
12.03.24	BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease (GlobeNewswire)
29.02.24	BioSenic S.A. : Information on the total number of voting rights and shares (GlobeNewswire)
02.02.24	BioSenic raises €500,000 in private placement of new shares with established new investors (GlobeNewswire)
31.01.24	BioSenic provides support to forthcoming European conference on graft-versus-host disease (GlobeNewswire)
30.01.24	BioSenic patent granted in Canada for broader protection of ATO therapeutic platform (GlobeNewswire)
25.01.24	BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress (GlobeNewswire)
23.01.24	BioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis (GlobeNewswire)
15.01.24	BioSenic S.A. : Transparency notifications received from François Rieger (GlobeNewswire)
15.01.24	BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment (GlobeNewswire)
10.01.24	BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer (GlobeNewswire)
08.01.24	BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds (GlobeNewswire)
08.12.23	ERRATUM: BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease (GlobeNewswire)
06.12.23	BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease (GlobeNewswire)
25.10.23	BioSenic provides third quarter 2023 Business Update (GlobeNewswire)
18.10.23	BioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure runway end of January 2024 (GlobeNewswire)
17.10.23	BioSenic S.A. : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS (GlobeNewswire)
05.10.23	BioSenic S.A. : Information on the total number of voting rights and shares (GlobeNewswire)
27.09.23	BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD (GlobeNewswire)
19.09.23	BioSenic publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis (GlobeNewswire)
14.09.23	BioSenic reaches agreement on binding term sheets with main creditors to restructure past financial debts (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bone Therapeutics S.A.

Aktien Top/Flop

Meistgelesene Nachrichten